Methylphenidate Delayed Release Composition for ADHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ADHD and other CNS stimulant-responsive conditions face challenges in maintaining effective drug concentrations throughout the day, particularly in morning and afternoon when cognitive abilities are needed, due to the rapid release of medications leading to compliance issues and side effects.
Innovation Solution
Development of novel pharmaceutical compositions with a core comprising a CNS stimulant, a sustained release layer, and a delayed release layer, allowing for a controlled release of the drug over 4 to 12 hours, enabling a therapeutic effect from waking to the active part of the day with a single evening dose, and adjustable lag time through formulation design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation is used, then rapid therapeutic effect is achieved, but compliance problems occur due to frequent dosing requirements
Solution Approach 1:
The patent segments the drug release into multiple distinct phases: an initial lag period with minimal release, followed by a sustained release phase, and potentially a final burst release phase. This segmentation allows the drug to be delivered in a controlled temporal pattern that maintains therapeutic levels throughout the day while requiring only once-daily dosing, thereby resolving the contradiction between rapid effect and compliance.
Solution Approach 2:
The formulation incorporates a preliminary lag period before significant drug release begins. This preliminary action delays the onset of release until the desired time (e.g., morning hours), allowing patients to take the medication once in the evening while achieving therapeutic effects during daytime cognitive activities, thus improving compliance without sacrificing therapeutic speed when needed.
2Ease of operation
If long-acting formulations are used, then compliance is improved with single daily dosing, but drug concentration is not maintained throughout the day
Solution Approach 1:
The patent employs dynamic release characteristics that adapt to the desired therapeutic profile: an initial lag phase with suppressed release, transitions to a sustained release phase that maintains steady drug levels, and potentially a final acceleration phase. This dynamic control ensures reliable maintenance of effective concentrations throughout daytime hours while preserving the compliance benefits of once-daily dosing.
Solution Approach 2:
The formulation changes the release rate parameter over time through its multi-phase design. By controlling the dissolution and diffusion parameters at different time points (lag period, sustained phase, burst phase), the system maintains reliable therapeutic concentrations during critical daytime periods while requiring only single evening administration, thus resolving the contradiction between compliance and concentration maintenance.
3Loss of time
If drug release is delayed, then therapeutic effect is achieved at the right time, but side effects are reduced due to avoided peak concentrations
Solution Approach 1:
The formulation uses a preliminary lag period to delay significant drug release until the desired therapeutic window (morning hours). This preliminary action avoids peak concentrations during evening hours when patients are taking the medication, thereby reducing side effects while ensuring therapeutic effect occurs at the appropriate time for daytime cognitive activities.
Solution Approach 2:
The patent implements periodic release patterns with distinct phases: a lag period with minimal release, a sustained release phase during daytime hours, and potentially a final burst phase. This periodic action timing the release to match when therapeutic effect is needed while avoiding periods when side effects would be problematic, thus resolving the contradiction between timing and side effect reduction.
Data Source
AI summary
Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.